Relmada Therapeutics Inc
Company Profile
Business description
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Contact
2222 Ponce de Leon Boulevard
Floor 3
Coral GablesFL33134
USAT: +1 786 629-1376
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
The World Cup stock you’ve never heard of
stocks
Chart of the Week: Can WiseTech shares finally bounce back?
stocks
Steep downgrade for wide moat share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,961.30 | 46.50 | 0.52% |
| CAC 40 | 8,273.77 | 21.11 | 0.26% |
| DAX 40 | 24,954.88 | 57.43 | 0.23% |
| Dow JONES (US) | 52,348.39 | 576.76 | -1.09% |
| FTSE 100 | 10,423.51 | 65.53 | -0.62% |
| HKSE | 24,030.18 | 169.28 | -0.70% |
| NASDAQ | 25,870.65 | 51.96 | 0.20% |
| Nikkei 225 | 67,743.85 | 924.80 | 1.38% |
| NZX 50 Index | 13,785.67 | 120.49 | 0.88% |
| S&P 500 | 7,482.71 | 21.14 | -0.28% |
| S&P/ASX 200 | 8,762.50 | 44.40 | 0.51% |
| SSE Composite Index | 4,036.59 | 65.71 | 1.65% |